Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-invasive and low-cost technique for early detection of clinically relevant breast lesions using a handheld point-of-care medical device (iBreast): Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries

Date

03 May 2019

Session

Poster lunch

Presenters

Ashwin KR

Citation

Annals of Oncology (2019) 30 (suppl_3): iii65-iii71. 10.1093/annonc/mdz101

Authors

A. KR

Author affiliations

  • Oncology, Manipal Comprehensive Cancer Center Manipal Hospital, 560017 - Bangalore/IN
More

Resources

Background

iBreast is an unique portable handheld non-invasive medical device which is developed in India to screen patients in rural and suburban areas. It employs a lead zirconate titanate piezoelectric cantilever sensor and can accurately detect abnormal areas by comparing the degree of deflection. Our tripled blinded study compares it with Clinical Breast Examination and Mammography and breast ultrasound.

Methods

1019 women visiting a tertiary Indian hospital, for annual health check were recruited. Each woman was examined by three independent methods, each blinded to the other two: iBreastExam (iBE), Clinical Breast Examination (CBE) by an expert clinician and Breast Imaging (mammography or breast ultrasound).

Results

Out of 916 enrolled participants, 93 were confirmed by imaging to have at least one breast lesion. Clinical Breast Examination in comparison with imaging detected breast lesions with Sn = 65 %, Sp = 94 %, PPV = 52 %, NPV = 96 %, and iBreastExam reported Sn = 84 %, Sp = 94 %, PPV = 60 % and NPV = 98 %. In women below age 40 (314 participants), iBE detected breast lesions with Sn = 85 %, Sp = 93 %. All malignant lesions were identified by iBE, while one non-palpable malignant lesion was missed by clinician CBE.

Conclusions

The point-of-care Breast Imaging device (iBreastExam) performed with significantly better sensitivity, by 19 %, than CBE to detect breast lesions while reporting high specificity (94 %) and NPV (98 %). In younger women population under the age of 40 years, where the prevalence of dense breast is high, iBreastExam demonstrated high-performance characteristics. iBreast- Exam detected all malignant lesions in this study, while the clinician’s CBE missed to detect a non-palpable malignant lesion. iBreastExam can be a promising tool to provide clinically effective and standardized breast examinations in low-resource settings to detect breast lesions at early stages. The device can also be an effective screening tool for younger women with dense breasts.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Manipal Coprehensive Cancer Center.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings